The prevalent KRAS exon 2 c.35 G>A mutation in metastatic colorectal cancer patients: A biomarker of worse prognosis and potential benefit of bevacizumab-containing intensive regimens?

Critical Reviews in Oncology/Hematology

Volumn 93, Issue 3, 2015, Pages 190-202

  Bruera, Gemma ^a   Cannita, Katia ^a   Tessitore, Alessandra ^a   Russo, Antonio ^b   Alesse, Edoardo ^a   Ficorella, Corrado ^a   Ricevuto, Enrico ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

Bevacizumab; Biomarker; Intensive regimens; KRAS c.35 G>A mutation; Metastatic colorectal cancer

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; GUANOSINE TRIPHOSPHATASE; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; VASCULOTROPIN INHIBITOR; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; KRAS PROTEIN, HUMAN; MONOCLONAL ANTIBODY; ONCOPROTEIN; RAS PROTEIN; VASCULOTROPIN A;

CANCER CHEMOTHERAPY; CODON; DRUG EFFICACY; EXON; GENOTYPE; HUMAN; METASTATIC COLORECTAL CANCER; MUTANT; ONCOGENE K RAS; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN FUNCTION; REVIEW; UPREGULATION; WILD TYPE; ANTAGONISTS AND INHIBITORS; COLORECTAL NEOPLASMS; DISEASE COURSE; GENETICS; METASTASIS; MORTALITY; MUTATION; MUTATION RATE; PATHOLOGY; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; EXONS; GENOTYPE; HUMANS; MUTATION; MUTATION RATE; NEOPLASM METASTASIS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84922453787     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2014.10.004     Document Type: Review

References (62)

1. Yarden Y., Sliwkowsky M.X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001, 2(2):127-137.
2. Scaltriti M., Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 2006, 12(18):5268-5272.
3. McCubrey J.A., Steelman L.S., Abrams S.L., Lee J.T., Chang F., Bertrand F.E., et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 2006, 46(1):249-279.
4. Forbes S., Clements J., Dawson E., Bamford S., Webb T., Dogan A., et al. Cosmic 2005. Br J Cancer 2006, 94:318-322.
5. Bos J.L. ras oncogenes in human cancer: a review. Cancer Res 1989, 49:4682-4689.
6. Andreyev H.J., Norman A.R., Cunningham D., Oates J., Dix B.R., Iacopetta B.J., et al. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 2001, 85(5):692-696.
7. Normanno N., Tejpar S., Morbillo F., De Luca A., Van Cutsem E., Ciardiello F. Implication of KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol 2009, 6:519-527.
8. Chen C.C., Er T.K., Liu Y.Y., Hwang J.K., Barrio M.J., Rodrigo M., et al. Computational analysis of KRAS mutations: implications for different effects on the KRAS p.G12D and p.G13D mutations. PLoS One 2013, 8(2):e55793.
9. Seeburg P.H., Colby W.W., Capon D.J., Goeddel D.V., Levinson A.D. Biological properties of human c-Ha-ras1 genes mutated at codon 12. Nature 1984, 312:71-75.
10. Schubbert S., Shannon K., Bollag G. Hyperactive ras in developmental disorders and cancer. Nat Rev Cancer 2007, 7:295-308.
11. Gibbs J.B., Sigal I.S., Poe M., Intrinsic Scolnick E.M. GTPase activity distinguishes normal and oncogenic ras p21 molecules. Proc Natl Acad Sci USA 1984, 81:5704-5708.
12. Al-Mulla F., Milner-White E.J., Going J.J., Birnie G.D. Structural differences between valine-12 and aspartate-12 Ras proteins may modify carcinoma aggression. J Pathol 1999, 187:433-438.
13. Rak J., Mitsuhashi Y., Sheehan C., Tamir A., Viloria-Petit A., Filmus J., et al. Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts. Cancer Res 2000, 60:490-498.
14. Rak J., Mitsuhashi Y., Bayko L., Filmus J., Shirasawa S., Sasazuki T., et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995, 55:4575-4580.
15. Watnick R.S., Cheng Y.N., Rangarajan A., Ince T.A., Weinberg R.A. Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell 2003, 3:219-231.
16. Monticone M., Bollo E., Maffei M., Donadini A., Romeo F., Storlazzi C.T., et al. Gene expression deregulation by KRAS G12D and G12V in a BRAF V600E context. Mol Cancer 2008, 7:92.
17. Guerrero S., Casanova I., Farrè L., Mazo A., Capellà G., Mangues R. K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res 2000, 60:6750-6756.
18. Bos J.L., Toksoz D., Marshall C.J., Verlaan-de Vries M., Veeneman G.H., van der Eb A.J., et al. Amino-acid substitutions at codon 13 of the N-ras oncogene in human acute myeloid leukaemia. Nature (London) 1985, 315:726-730.
19. Andreyev H.J.N., Norman A.R., Cunningham D., Oates J.R., Clarke P.A. Kirsten ras mutations in patients with colorectal cancer: the multicenter 'RASCAL' study. J Natl Cancer Inst 1998, 90(9):675-684.
20. Imamura Y., Morikawa T., Liao X., Lochhead P., Kuchiba A., Yamauchi M., et al. Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF-wild-type colorectal cancers. Clin Cancer Res 2012, 18(17):4753-4763.
21. Samowitz W.S., Curtin K., Schaffer D., Robertson M., Leppert M., Slattery M.L. Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomark Prev 2000, 9:1193-1197.
22. Westra J.L., Schaapveld M., Hollema H., de Boer J.P., Kraak M.M.J., de Jong D., et al. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. J Clin Oncol 2005, 23:5635-5643.
23. Bruera G., Cannita K., Giordano A.V., Vicentini R., Ficorella C., Ricevuto E. Effectiveness and safety of intensive triplet chemotherapy plus bevacizumab, FIr-B/FOx, in young-elderly Metastatic Colorectal Cancer (MCRC) patients. BioMed Res Int 2013, 2013:143273.
24. Bruera G., Cannita K., Giordano A.V., Vicentini R., Ficorella C., Ricevuto E. Prognostic relevance of KRAS genotype in metastatic colorectal cancer patients unfit for FIr-B/FOx intensive regimen. Int J Oncol 2014, 44(6):1820-1830.
25. Bruera G., Santomaggio A., Cannita K., Lanfiuti Baldi P., Tudini M., De Galitiis F., et al. Poker association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study. BMC Cancer 2010, 10:67.
26. Bruera G., Cannita K., Giuliante F., Lanfiuti Baldi P., Vicentini R., Marchetti P., et al. Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab. Clin Colorectal Cancer 2012, 11(2):119-126.
27. Bruera G., Cannita K., Giordano A.V., Vicentini R., Ficorella C., Ricevuto E. Differential prognosis of metastatic colorectal cancer patients post-progression to first line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second line treatment and KRAS genotype. Int J Oncol 2014, 44(1):17-26.
28. Di Nicolantonio F., Martini M., Molinari F., Sartore-Bianchi A., Arena S., Saletti P., et al. Wild-type BRAF is required for response to panitumumab and cetuximab in metastatic colorectal cancer. J Clin Oncol 2008, 26(35):5705-5712.
29. Ince W.L., Jubb A.M., Holden S.N., Holmgren E.B., Tobin P., Sridhar M., et al. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst 2005, 97(13):981-989.
30. Hurwitz H.I., Yi J., Ince W., Novotny W.F., Rosen O. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. The Oncologist 2009, 14:22-28.
31. Bruera G., Cannita K., Di Giacomo D., Lamy A., Troncone G., Dal Mas A., et al. Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease. BMC Med 2012, 10(1):135.
32. Bruera G., Ricevuto E. Intensive chemotherapy of metastatic colorectal cancer: weighing between safety and clinical efficacy. Evaluation of Masi G, Loupakis F, Salvatore L, et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 2010, 11:845-852. Expert Opin Biol Ther 2011;11(6):821-824.
33. Etienne-Grimaldi M.C., Formento J.L., Francoual M., Francois E., Formento P., Renee N., et al. K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin Cancer Res 2008, 14(15):4830-4835.
34. Van Cutsem E., Kohne C.H., Hitre E., Zaluski J., Chang Chien C.R., Makhson A., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009, 351:1408-1417.
35. Bokemeyer C., Bondarenko I., Makhson A., Hartmann J.T., Aparicio J., de Braud F., et al. Fluorouracil, leucoverin, and oxaliplatin with or without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009, 27:663-671.
36. Karapetis C.S., Khambata-Ford S., Jonker D.J., O'Callaghan C.J., Tu D., Tebbutt N.C., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008, 359:1757-1765.
37. Van Cutsem E., Peeters M., Siena S., Humblet Y., Hendlisz A., Neyns B., et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007, 25:1658-1664.
38. Amado R.G., Wolf M., Peeters M., Van Cutsem E., Siena S., Freeman D.J., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:1626-1634.
39. Peeters M., Price Y.J., Cervantes A., Sobrero A.F., Ducreux M., Hotko Y., et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010, 28:4706-4713.
40. Van Cutsem E., Köhne C.H., Làng I., Folprecht G., Nowacki M.P., Cascinu S., et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011, 29:2011-2019.
41. Bokemeyer C., Bondarenko I., Hartmann J.T., de Braud F., Schuch G., Zubel A., et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011, 22:1535-1546.
42. Tejpar S., Celik I., Schlichting M., Sartorius U., Bokemeyer C., Van Cutsem E. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol 2012, 30(29):3570-3577.
43. De Roock W., Jonker D.J., Di Nicolantonio F., Sartore-Bianchi A., Tu D., Siena S., et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. J Am Med Assoc 2010, 304(16):1812-1820.
44. Mao C., Huang Y.F., Yang Z.Y., Zheng D.Y., Chen J.Z., Tang J.L. KRAS p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer. Cancer 2013, 119(4):714-721.
45. Chen J., Ye Y., Sun H., Shi G. Association between KRAS codon 13 mutations and clinical response to anti-EGFR treatment in patients with metastatic colorectal cancer: results from a meta-analysis. Cancer Chemother Pharmacol 2013, 71(1):265-272.
46. Peeters M., Douillard J.Y., Van Cutsem E., Siena S., Zhang K., Williams R., et al. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. J Clin Oncol 2013, 31(6):759-765.
47. Douillard J.Y., Oliner K.S., Siena S., Tabernero J., Burkes R., Barugel M., et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013, 369(11):1023-1034.
48. Schwartzberg L.S., Rivera F., Karthaus M., Fasola G., Canon J.L., Hecht J.R., et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 2014, 32(21):2240-2247.
49. Stintzing S, Jung A, Rossius L, Modest DP, Fischer von Weikersthal L, Decker T, et al. Phase III FIRE-3 trial data show most patients with wild-type RAS metastatic colorectal cancer benefit from first-line FOLFIRI plus cetuximab treatment. ESMO-ECCO congress; 2013.
50. Ciardiello F., Lenz H.J., Kohne C.H., Heinemann V., Tejpar S., Esser R., et al. Effect of KRAS and NRAS mutational status on first-line treatment with FOLFIRI plus cetuximab in patients with metastatic colorectal cancer (mCRC): new results from the CRYSTAL trial. J Clin Oncol 2014, 32. (suppl 3; abstr LBA443).
51. Tejpar S., Lenz H.J., Köhne C.H., Heinemann V., Ciardiello F., Esser R., et al. Effect of KRAS and NRAS mutations on treatment outcomes in patients with metastatic colorectal cancer (mCRC) treated first-line with cetuximab plus FOLFOX4: new results from the OPUS study. J Clin Oncol 2014, 32. (suppl 3; abstr LBA444).
52. Cremolini C., Loupakis F., Lonardi S., Tomasello G., Ronzoni M., Zaniboni A., et al. Subgroup analyses in RAS mutant, BRAS mutant and all wt metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab (BEV) versus FOLFIRI plus BEV in the TRIBE study. Ann Oncol 2014, 25(2 Suppl):ii105-ii117. (O-0007).
53. Bruera G., Cannita K., Di Giacomo D., Lamy A., Frébourg T., Sabourin J.C., et al. Worse prognosis of KRAS c.35 G>A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx). BMC Med 2013, 11(1):59.
54. Masi G., Loupakis F., Salvatore L., Fornaro L., Cremolini C., Cupini S., et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 2010, 11:845-852.
55. Diaz-Rubio E., Gomez-Espana A., Massuti B., Sastre J., Reboredo M., Manzano J.L., et al. Role of Kras status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: a TTD group cooperative study. PLoS One 2014, 7(10):e47345.
56. Gideon P., John J., Frech M., Lautwein A., Clark R., Scheffler J.E., et al. Mutational and kinetic analyses of the GTPase-activating protein (GAP)-p21 interaction: the C-terminal domain of GAP is not sufficient for full activity. Mol Cell Biol 1992, 12:2050-2056.
57. Malumbres M., Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer 2003, 3:459-465.
58. Chin L., Tam A., Pomerantz J., Wong M., Holash J., Bardeesy N., et al. Essential role for oncogenic Ras in tumour maintenance. Nature 1999, 400:468-472.
59. Figueras A., Arbos M.A., Quiles M.T., Vinals F., Germà J.R., Capellà G. The impact of KRAS mutations on VEGF-A production and tumour vascular network. BMC Cancer 2013, 13:125.
60. Yu J.L., Rak J.W., Coomber B.L., Hicklin D.J., Kerbel R.S. Effect of p53 status on tumor response to antiangiogenic therapy. Science 2002, 295:1526-1528.
61. Bouvet M., Ellis L.M., Nishizaki M., Fujiwara T., Liu W., Bucana C.D., et al. Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Cancer Res 1998, 58:2288-2292.
62. Dameron K.M., Volpert O.V., Tainsky M.A., Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994, 265:1582-1584.